191 related articles for article (PubMed ID: 21232794)
1. A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.
Pekova S; Mazal O; Cmejla R; Hardekopf DW; Plachy R; Zejskova L; Haugvicova R; Jancuskova T; Karas M; Koza V; Smolej L; Bezdickova L; Kozak T
Leuk Res; 2011 Jul; 35(7):889-98. PubMed ID: 21232794
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
4. Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.
de Viron E; Knoops L; Connerotte T; Smal C; Michaux L; Saussoy P; Vannuffel P; Beert E; Vekemans MC; Hermans C; Bontemps F; Van Den Neste E
Br J Haematol; 2009 Dec; 147(5):641-52. PubMed ID: 19764992
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
[TBL] [Abstract][Full Text] [Related]
6. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.
Zainuddin N; Murray F; Kanduri M; Gunnarsson R; Smedby KE; Enblad G; Jurlander J; Juliusson G; Rosenquist R
Leuk Res; 2011 Feb; 35(2):272-4. PubMed ID: 20870288
[TBL] [Abstract][Full Text] [Related]
7. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
Chang H; Jiang AM; Qi CX
Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
[TBL] [Abstract][Full Text] [Related]
8. Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia?
Marinelli M; Raponi S; Del Giudice I; De Propris MS; Nanni M; Intoppa S; Milani ML; Mauro FR; Guarini A; Foà R
Am J Clin Pathol; 2011 Jan; 135(1):173-4. PubMed ID: 21173142
[No Abstract] [Full Text] [Related]
9. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.
Kienle DL; Korz C; Hosch B; Benner A; Mertens D; Habermann A; Kröber A; Jäger U; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2005 Jun; 23(16):3780-92. PubMed ID: 15867199
[TBL] [Abstract][Full Text] [Related]
10. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C
Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282
[TBL] [Abstract][Full Text] [Related]
11. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.
Fabris S; Mosca L; Todoerti K; Cutrona G; Lionetti M; Intini D; Matis S; Colombo M; Agnelli L; Gentile M; Spriano M; Callea V; Festini G; Molica S; Lambertenghi Deliliers G; Morabito F; Ferrarini M; Neri A
Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
[TBL] [Abstract][Full Text] [Related]
13. Identification of somatic hypermutations in the TP53 gene in B-cell chronic lymphocytic leukemia.
Malcikova J; Smardova J; Pekova S; Cejkova S; Kotaskova J; Tichy B; Francova H; Doubek M; Brychtova Y; Janek D; Pospisilova S; Mayer J; Dvorakova D; Trbusek M
Mol Immunol; 2008 Mar; 45(5):1525-9. PubMed ID: 17920683
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.
Malcikova J; Pavlova S; Kozubik KS; Pospisilova S
Hum Mutat; 2014 Jun; 35(6):663-71. PubMed ID: 24415659
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia.
Nakagawa Y; Yamaguchi S; Hasegawa M; Nemoto T; Inoue M; Suzuki K; Hirokawa K; Kitagawa M
Leuk Res; 2004 May; 28(5):487-94. PubMed ID: 15068902
[TBL] [Abstract][Full Text] [Related]
16. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.
Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G
Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202
[TBL] [Abstract][Full Text] [Related]
17. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia.
Carter A; Lin K; Sherrington PD; Pettitt AR
Br J Haematol; 2004 Nov; 127(4):425-8. PubMed ID: 15521919
[TBL] [Abstract][Full Text] [Related]
18. Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B.
Kalla C; Scheuermann MO; Kube I; Schlotter M; Mertens D; Döhner H; Stilgenbauer S; Lichter P
Eur J Cancer; 2007 May; 43(8):1328-35. PubMed ID: 17449237
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
Mittal AK; Hegde GV; Aoun P; Bociek RG; Dave BJ; Joshi AD; Sanger WG; Weisenburger DD; Joshi SS
Int J Mol Med; 2007 Oct; 20(4):461-9. PubMed ID: 17786276
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations.
Zenz T; Vollmer D; Trbusek M; Smardova J; Benner A; Soussi T; Helfrich H; Heuberger M; Hoth P; Fuge M; Denzel T; Häbe S; Malcikova J; Kuglik P; Truong S; Patten N; Wu L; Oscier D; Ibbotson R; Gardiner A; Tracy I; Lin K; Pettitt A; Pospisilova S; Mayer J; Hallek M; Döhner H; Stilgenbauer S;
Leukemia; 2010 Dec; 24(12):2072-9. PubMed ID: 20861914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
